Steminent Biotherapeutics (ROCO:7729) Beginning Cash Position: NT$132.46 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7729 Steminent Biotherapeutics Inc ROCO:7729
11 GF Score
Price NT$79.90
! 4 Warning Signs
View Full Analysis

What is Steminent Biotherapeutics Beginning Cash Position?

Steminent Biotherapeutics ROCO:7729 +0.38% 11 Beginning Cash Position is NT$132.46 Mil as of Dec. 2025. GuruFocus rates ROCO:7729 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Steminent Biotherapeutics's Beginning Cash Position for the quarter that ended in Dec. 2025 was NT$132.46 Mil.

Steminent Biotherapeutics's quarterly Beginning Cash Position declined from Dec. 2024 (NT$318.03 Mil) to Jun. 2025 (NT$205.40 Mil) and declined from Jun. 2025 (NT$205.40 Mil) to Dec. 2025 (NT$132.46 Mil).

Steminent Biotherapeutics's annual Beginning Cash Position increased from Dec. 2023 (NT$153.43 Mil) to Dec. 2024 (NT$451.86 Mil) but then declined from Dec. 2024 (NT$451.86 Mil) to Dec. 2025 (NT$205.40 Mil).

Steminent Biotherapeutics Beginning Cash Position Related Terms

Steminent Biotherapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Steminent Biotherapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics Beginning Cash Position Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 40.81 230.56 153.43 451.86 205.40

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 360.39 451.86 318.03 205.40 132.46
ROCO:7729
11GF Score
Steminent Biotherapeutics Inc ROCO:7729
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steminent Biotherapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$132.46 Mil mean?
Steminent Biotherapeutics (ROCO:7729) has a Beginning Cash Position of NT$132.46 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Steminent Biotherapeutics and its competitors.
Is Steminent Biotherapeutics' Beginning Cash Position too high?
Steminent Biotherapeutics' current Beginning Cash Position is NT$132.46 Mil. Overall, Steminent Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' Beginning Cash Position compare to VRTX and REGN?
Steminent Biotherapeutics' Beginning Cash Position of NT$132.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Steminent Biotherapeutics and its competitors. Steminent Biotherapeutics's current Beginning Cash Position is NT$132.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current Beginning Cash Position of NT$132.46 Mil. The current Beginning Cash Position is NT$132.46 Mil. Steminent Biotherapeutics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current Beginning Cash Position is NT$132.46 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Steminent Biotherapeutics Business Description

Address No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
11GF Score

Get the complete analysis for ROCO:7729

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$79.90
Price